(Reuters) - U.S. regulators have granted priority review for AbbVie Inc's experimental all-oral regimen for patients infected with the most common genotype of hepatitis C virus, the company said on Friday.
The priority review means the Food and Drug Administration will likely decide within six months whether to approve the regimen, which was submitted to the agency on April 21.
Also read: Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
Read more